#PRESS #AscendisPharma announces our Q3 2024 results and provides a business update. Learn more on the Investors & News section of our website.
Ascendis Pharma
Forskning inden for bioteknologi
Hellerup, Capital Region of Denmark 59.767 følgere
Committed to making a meaningful difference for patients
Om os
Ascendis Pharma is applying our innovative TransCon technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our TransCon technology platform to create new and potentially best-in-class therapies. Ascendis Pharma currently has three independent endocrinology rare disease product candidates in clinical development and we're also advancing programs in Oncology and Ophthalmology. Ascendis Pharma is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg, Munich, and Berlin, Germany, Palo Alto and Redwood City, California, and Princeton, New Jersey.
- Websted
-
http://www.ascendispharma.com
Eksternt link til Ascendis Pharma
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 501 – 1.000 medarbejdere
- Hovedkvarter
- Hellerup, Capital Region of Denmark
- Type
- Aktieselskab
- Grundlagt
- 2007
- Specialer
- Endocrinology, Oncology, Drug Development, Innovation, Globalization , Ophthalmology og TransCon Technology
Beliggenheder
-
Primær
Se ruten
Tuborg Boulevard 12
Hellerup, Capital Region of Denmark 2900, DK
Medarbejdere hos Ascendis Pharma
Opdateringer
-
During #FamilyCaregiversMonth, #AscendisPharma recognizes caregivers everywhere who offer unwavering support and compassion.
-
-
#AscendisPharma is looking forward to attending the HypoPARAthyroidism Association International #HypoPARAthyroidism Conference this weekend! We look forward to connecting with the #hypoPARA community and hearing from experts about the latest on this #raredisease.
-
-
#HCPs #AscendisPharma is attending this year’s American Thyroid Association (ATA) annual meeting in Chicago. We look forward to seeing you there! #atathyroid2024
-
-
Today, #AscendisPharma supports #InternationalDwarfismAwarenessDay and the efforts to broaden awareness of the history, pride and empowerment of the dwarfism community.
-
-
#HCPs #AscendisPharma is excited to attend this year’s #KidneyWk in San Diego, presented by the American Society of Nephrology.
-
-
The #AscendisPharma U.S. team is looking forward to attending this year’s #AMCPNexus 2024 in Las Vegas from October 14-17.
-
-
The #AscendisPharma U.S. team is attending the 2024 PCMA Annual Meeting. We look forward to connecting with pharmaceutical industry professionals in Phoenix.
-
-
#HCPs At this year’s #ASBMR2024, #AscendisPharma will share new 162-week skeletal dynamics results from the Phase 2 PaTH Forward clinical trial in adults with chronic #hypoparathyroidism.
-
-
#HCPs #AscendisPharma is heading to Toronto for the #ASBMR2024 annual meeting! We look forward to seeing you there.
-
Tilsvarende sider
Finansiering
Ascendis Pharma
8 runder i alt
Læs mere på crunchbase
Seneste runde
Post IPO-egenkapital
Eksternt Crunchbase-link til seneste finansieringsrunde
300.000.000,00 US$